Liprolog Junior Kwikpen

Insulin lispro, the active ingredient in Liprolog Junior Kwikpen, is a rapid‑acting insulin analog presented as a pre‑filled pen injector for subcutaneous administration. It is used to lower elevated blood glucose levels in individuals with type 1 and type 2 diabetes mellitus.

GNH USA supplies Liprolog Junior Kwikpen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable and timely access to this EU‑origin insulin product for clinical use, meeting stringent quality standards and cold‑chain logistics where required.

Insulin lispro is a rapid‑acting insulin analog used in the management of diabetes mellitus.

- Type 1 diabetes mellitus: provides rapid reduction of post‑prandial glucose levels. - Type 2 diabetes mellitus: assists in controlling mealtime glucose excursions. - Post‑prandial hyperglycaemia: helps achieve target blood glucose after meals.

Insulin lispro may cause a range of adverse reactions.

Common Side Effects: - Hypoglycaemia: low blood sugar episodes. - Injection site pain or erythema. - Lipodystrophy at the injection site. - Weight gain. - Local allergic reaction. - Transient nausea.

Serious or Rare Side Effects: - Severe hypoglycaemia with neuroglycopenic symptoms. - Anaphylactic reaction. - Hypokalemia. - Severe allergic reaction such as urticaria or angio‑edema.

When using Liprolog Junior Kwikpen, consider the following precautions.

- Dose adjustment: tailor dose based on regular blood glucose monitoring. - Renal impairment: monitor closely as insulin clearance may be reduced. - Hepatic impairment: use with caution due to altered insulin metabolism. - Pregnancy and lactation: assess risk‑benefit with a healthcare professional. - Hypoglycaemia risk: educate patients on recognizing and treating low blood sugar. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulin lispro can interact with several medicines.

Major Interactions (Avoid): - Beta‑blockers: may mask hypoglycaemia symptoms. - MAO inhibitors: can potentiate insulin’s glucose‑lowering effect.

Moderate Interactions (Monitor Closely): - Oral hypoglycaemic agents (e.g., sulfonylureas, meglitinides): increase hypoglycaemia risk. - ACE inhibitors: may enhance insulin sensitivity. - Thiazide diuretics: may raise blood glucose levels. - Corticosteroids: may increase insulin requirements.